Ryan David Morin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan David Morin has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- David W. Scott
Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada
72 shared publications - Laura K. Hilton
BC Cancer, Vancouver, British Columbia, Canada
63 shared publications - Kojo S. J. Elenitoba-Johnson
Memorial Sloan Kettering Cancer Center Department of Pathology and Laboratory Medicine New York, New York
54 shared publications - Kostiantyn Dreval
Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada
52 shared publications - Ari M. Melnick
Cornell University
38 shared publications - Matt Teater
Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York
37 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by American Society of Hematology in Blood
A single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes
Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we performed single-cell RNA-seq, BCR-seq, and TCR-seq on LBCL tumor biopsies, generating an atlas of 63 LBCL cases, mostly classified as diffuse LBCL, not otherwise specified (DLBCL NOS). We identified five conserved transcriptional archetypes of malignant B cells that co-occur within individual tumors, with varying proportions across patients. Notably, high abundance of Archetype 4, characterized by memory B cell features and quiescence markers, correlated with poor event-free survival following standard immunochemotherapy, a finding which was validated in independent cohorts through deconvolution of bulk RNA-seq data. Our study provides a novel framework for patient stratification based on the quantification of malignant cellular states, with implications for precision therapy of LBCLs.
- 17 September 2026
- Published by American Society of Hematology in Blood
Open AccessA single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes
Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we performed single-cell RNA-seq, BCR-seq, and TCR-seq on LBCL tumor biopsies, generating an atlas of 63 LBCL cases, mostly classified as diffuse LBCL, not otherwise specified (DLBCL NOS). We identified five conserved transcriptional archetypes of malignant B cells that co-occur within individual tumors, with varying proportions across patients. Notably, high abundance of Archetype 4, characterized by memory B cell features and quiescence markers, correlated with poor event-free survival following standard immunochemotherapy, a finding which was validated in independent cohorts through deconvolution of bulk RNA-seq data. Our study provides a novel framework for patient stratification based on the quantification of malignant cellular states, with implications for precision therapy of LBCLs.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Containing Gating Strategies and Code
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Containing Gating Strategies and Code
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.